Pathways’ Picks September 1: China Picks, OMB Docket, and More to Watch

article image

In this week’s roundup: China’s National Medical Products Administration issues regulatory documents for implementing recent reforms and guidance documents on nanotechnology, artificial ligaments, and other topics. Also, a new Medicare Coverage of Innovative Technology proposal is under administrative review, FDA launched a 510(k) submissions tracker, and more.

China Picks

Developments at China’s NMPA:

(All linked documents are in Simplified Chinese)

China reg measures. The National Medical Products Administration issued new “administrative measures” for its medical device and IVD registration and filing rules on August 31. The measures, which will take effect October 1, are largely intended to help implement overall reforms to NMPA’s device/IVD regulations that went forward this summer. (See “New Chinese Medtech Regs Offer New Opportunities,” Market Pathways, August 4, 2021.) The measures address details related to evolving approaches in China to clinical trial exemptions, foreign certification requirements, inspection regimes, and an array of other issues. 


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: